About Us

At Zyngenia, we are developing the next generation of antibody-based drugs called Zybodies™. We are spearheading the development of this novel class of drugs to create more potent and more broadly acting protein therapeutics for the treatment of cancer, autoimmune and inflammatory diseases.

 

Zybodies™ are designed to incorporate the traditional attributes of monoclonal antibodies (mAbs) such as stability, ease of production, half-life, and effector function, into a single antibody-like protein that is able to interact with multiple targets.  This multi-specificity of Zybodies™ enables them to recognize two, three, or four different antigens concomitantly (termed “single protein-combination therapy”) and it is this feature that distinguishes them from conventional monoclonal antibodies that recognize a single target.

 

Diseases are most commonly caused by defects in multiple pathways; in cancer and autoimmune diseases combination therapies (of different drugs) are becoming the standard of care.   The inherent advantages of a Zybody™ are inherent to its ability to modulate simultaneously several biochemical pathways, cell types or tissues that are associated with a given disease state.  Thus Zybodies™ open the door to more effective and broadly acting therapies than those currently available with biologics that address a single target.  Moreover, the combination of multiple activities into a single Zybody™ will result in significantly lower development, manufacturing and administration costs and hurdles than those that are associated with existing combination therapies of two or more separate biological therapeutics.

 

In the future, Zyngenia’s technology of single protein-combination therapy technology will have novel applications in the development of therapeutics for disease targets that are not currently approachable with single agents or even with combinations of single agents.  The ability of a single molecule to recognize a repertoire of epitopes or antigens will allow the generation of novel activities and/or novel target recognition that arises solely because of the multi-antigen/epitope recognition characteristics of the Zybody™.  Zyngenia will use these properties of the molecule to address important cells and tissues in cancer and inflammation that hitherto have been very difficult to target.